Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu; Zylfije Hundozi; Faton Sermaxhaj; Afrim Blyta; Nexhmedin Shala; Fisnik Jashari; Hasime Qorraj Bytyqi; Ekrem Hyseni; Ilir Kurtishi

doi:10.12659/MSM.937856

31 August 2022 : Clinical Research

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu^12ABCDEFG*, Zylfije Hundozi^12ACDF, Faton Sermaxhaj^3ABD, Afrim Blyta^1ACDF, Nexhmedin Shala^12CD, Fisnik Jashari^12C, Hasime Qorraj Bytyqi^4CDF, Ekrem Hyseni^3BC, Ilir Kurtishi^3BC

DOI: 10.12659/MSM.937856

Med Sci Monit 2022; 28:e937856

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Type of diagnosed cancer and distribution by number, age, and sex.

Cancer type	Number	Age (Mean±SD)	Female/Male
Breast	24	55.4±12.8	24/0

Oro-esophageal	3	57.6±14.4	2/1

Gastric	18	60±8.2	4/14

Colon	22	62.7±8.1	10/12

Rectal	4	69±5.4	2/2

Lung	17	63.7±7.4	2/15

Pancreatic	8	58.3±8.7	5/3

Ovarian	7	57±14.3	7/0

Endometrial	3	60.3±8.6	3/0

Testicular	1	34	0/1

Germ cell	2	37±19.7	1/1

Gallbladder	3	59.3±5.1	1/2

Urinary	2	70±7.0	0/2

Renal cell	1	55	1/0

Pharyngeal	1	66	0/1

Laryngeal	2	61±1.4	0/2

Melanoma	1	55	0/1

Hodgkin	1	26	1/0




SD – standard deviation.

Back to the Article

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Your Privacy